US Stock Move | Pneumococcal vaccine achieves late-stage clinical trial target, Vaxcyte (PCVX.US) opens more than 50% higher

According to Zhihu Finance APP, on Monday, Vaxcyte (PCVX.US) opened more than 50% higher, and as of press time, the share price had risen about 53%, with a market value of $12.8 billion. According to reports, the company's pneumococcal vaccine reached its late-stage clinical trial goals. Based on the company’s evaluation, VAX-31—a 31-valent pneumococcal conjugate vaccine still in the research phase—achieved positive topline results in the pivotal Phase III OPUS-1 trial. This trial evaluated the candidate vaccine’s safety, tolerability, and immunogenicity in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia. In the OPUS-1 trial, VAX-31 met all pre-specified co-primary immunogenicity endpoints in subjects aged 50 and above. These trial results will establish the foundation for the upcoming Biologics License Application submission to the U.S. Food and Drug Administration.